CONSTANTINE N. LOGOTHETIS1, NATHAN P. HORVAT2, TONY KURIAN3, CELESTE BELLO3, JULIO CHAVEZ3, LEIDY ISENALUMHE3, BIJAL SHAH3, LUBOMIR SOKOL3, HAYDER SAEED3, JAVIER PINILLA3, SAMEH GABALLA3,*
Oncology Research, Vol.32, No.6, pp. 1031-1036, 2024, DOI:10.32604/or.2024.046885
Abstract Extranodal marginal zone lymphoma (EMZL) encompasses 70% of cases of marginal zone lymphoma. Frontline bendamustine and rituximab (BR) were derived from trials involving other indolent non-Hodgkin’s lymphomas. Only one trial has evaluated frontline BR prospectively in EMZL. This retrospective study reports outcomes among EMZL patients receiving frontline BR. Twenty-five patients were included with a median age of 69 years (40–81). Five (20.0%) patients had stage I/II disease, and 20 (80.0%) had stage III/IV disease. The median number of cycles was 6.0 (3.0–6.0). Maintenance rituximab was administered to 10 (41.7%) individuals. Overall response rate (ORR) was More >
Login
Register
